Global Pharmacovigilance Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global pharmacovigilance market size is expected to reach USD 11.78 billion by 2026 and it is projected to expand at a CAGR of 13.3% during the forecast period 2019 to 2026.

Increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services.

Increasing acceptance and adoption of outsourcing services by healthcare companies will stimulate pharmacovigilance (PV) market growth in forthcoming years. Outsourcing eliminates the risk of business overhead costs as well as deployment of a pharmacovigilance resources. Outsourcing strategy increases the cost-effectiveness and efficiency by relieving resource pressure on firms. Positively shifting trends in PV outsourcing owing to increasing benefits will accelerate pharmacovigilance business growth in the coming years.

Rising number of adverse drug reactions (ADRs) will contribute to significant increase in the market size over the forecast period. According to National Centre for Biotechnology Information (NCBI), number of fatalities due to ADRs increased more than two-fold in 2014. This further led to increase in hospitalizations. Similarly, according to data by Clinics, 2018, there was 10.3% increase in ADR rate in Brazil per medication introduced during hospitalization. Such escalating number of ADRs that require continuous pharmacovigilance will render lucrative growth opportunity for pharmacovigilance market to facilitate effective surveillance of ADRs.

Accelerating demand for personalized medicines will impel momentous industry growth in the foreseeable future. Innovations in personalized medicine will offer growth potential to the market in ways to develop and quantitate risks and benefits of personalized medicines. Increasing advancement in targeted drugs such as new product development will further propel demand for pharmacovigilance services in the coming years.

Dearth of skilled healthcare professionals needed to analyse data and implement solutions can restrict market growth. Moreover, increased risk for data security that can be misused by the pharmacovigilance personnel can hamper business growth over the coming years.

Further key findings from the study suggest:

  • Phase IV held a dominant market share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market
  • Phase III is anticipated to witness lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring
  • In service provider segment, contract outsourcing held a significant market share, owing to shift in focus of pharmaceutical companies to outsourcing services to reduce operational cost
  • Based on type of service, spontaneous reporting held the largest market share owing to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
  • Research organizations segment is anticipated to exhibit lucrative CAGR over the forecast period owing to increasing R&D for the development of novel biologics and medical devices
  • Asia Pacific pharmacovigilance market is anticipated to showcase lucrative CAGR in the forthcoming years
  • Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services.

The top players in this market are Clinquest Group B.V., Accenture, Plc, Cognizant Technology Solutions, iMED Global Corporation, Covance, Inc. ICON, Plc, inVentiv Health, Inc., Pharmaceutical Product Development LLC, Parexel International Corporation, PRA Health Sciences, Inc., F. Hoffmann-La Roche Ltd., Quintiles Transnational Holdings Inc, Sanofi , Wipro Limited, and Synowledge LLC, among others.

Segmentation:

Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2015 - 2026)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2015 - 2026)

  • In-house
  • Contract Outsourcing

Pharmacovigilance Type of Methods Outlook (Revenue, USD Million, 2015 - 2026)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance End Use Outlook (Revenue, USD Million, 2015 - 2026)

  • Hospitals
  • Research Organizations
  • Industrial

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America
    • S.
    • Canada
  • Europe
    • K.
    • Germany
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa
    • Saudi Arabia

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Pharmacovigilance Market, By Service Provider

7.1.  Pharmacovigilance Market, By Service Provider, 2020-2030

7.1.1.    In-house

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Contract Outsourcing

7.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Pharmacovigilance Market, By Product Life Cycle

8.1.  Pharmacovigilance Market, By Product Life Cycle, 2020-2030

8.1.1.    Pre-clinical

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Phase I

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Phase II

8.1.3.1.        Market Revenue and Forecast (2016-2030)

8.1.4.    Phase III

8.1.4.1.        Market Revenue and Forecast (2016-2030)

8.1.5.    Phase IV

8.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Pharmacovigilance Market, By Type

9.1.  Pharmacovigilance Market, By Type, 2020-2030

9.1.1.    Spontaneous Reporting

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Intensified ADR Reporting

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Targeted Spontaneous Reporting

9.1.3.1.        Market Revenue and Forecast (2016-2030)

9.1.4.    Cohort Event Monitoring

9.1.4.1.        Market Revenue and Forecast (2016-2030)

9.1.5.    EHR Mining

9.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Pharmacovigilance Market, By Process Flow

10.1.        Pharmacovigilance Market, By Process Flow, 2020-2030

10.1.1.  Case Data Management

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Signal Detection

10.1.2.1.      Market Revenue and Forecast (2016-2030)

10.1.3.  Risk Management System

10.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Pharmacovigilance Market, By Therapeutic Area

11.1.        Pharmacovigilance Market, By Therapeutic Area, 2020-2030

11.1.1.  Oncology

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Neurology

11.1.2.1.      Market Revenue and Forecast (2016-2030)

11.1.3.  Cardiology

11.1.3.1.      Market Revenue and Forecast (2016-2030)

11.1.4.  Respiratory Systems

11.1.4.1.      Market Revenue and Forecast (2016-2030)

11.1.5.  Others

11.1.5.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Pharmacovigilance Market, By End-use

12.1.        Pharmacovigilance Market, By Product Life Cycle, 2020-2030

12.1.1.  Pharmaceuticals

12.1.1.1.      Market Revenue and Forecast (2016-2030)

12.1.2.  Biotechnology Companies

12.1.2.1.      Market Revenue and Forecast (2016-2030)

12.1.3.  Medical Device Manufacturers

12.1.3.1.      Market Revenue and Forecast (2016-2030)

12.1.4.  Other

12.1.4.1.      Market Revenue and Forecast (2016-2030)

Chapter 13.      Global Pharmacovigilance  Market, Regional Estimates and Trend Forecast

13.1.        North America

13.1.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

13.1.2.  Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.1.3.  Market Revenue and Forecast, By Type (2016-2030)

13.1.4.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.1.5.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.1.6.  Market Revenue and Forecast, By End-use (2016-2030)

13.1.7.  U.S.

13.1.7.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.1.7.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.1.7.3.      Market Revenue and Forecast, By Type (2016-2030)

13.1.7.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.1.8.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.1.8.1.      Market Revenue and Forecast, By End-use (2016-2030)

13.1.9.  Rest of North America

13.1.9.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.1.9.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.1.9.3.      Market Revenue and Forecast, By Type (2016-2030)

13.1.9.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.1.10.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.1.11.               Market Revenue and Forecast, By End-use (2016-2030)

13.1.11.1.    

13.2.        Europe

13.2.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

13.2.2.  Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.2.3.  Market Revenue and Forecast, By Type (2016-2030)

13.2.4.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.2.5.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.2.6.  Market Revenue and Forecast, By End-use (2016-2030)

13.2.7.   

13.2.8.  UK

13.2.8.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.2.8.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.2.8.3.      Market Revenue and Forecast, By Type (2016-2030)

13.2.9.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.2.10.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.2.10.1.   Market Revenue and Forecast, By End-use (2016-2030)

13.2.11.               Germany

13.2.11.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.2.11.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.2.11.3.   Market Revenue and Forecast, By Type (2016-2030)

13.2.12.               Market Revenue and Forecast, By Process Flow (2016-2030)

13.2.13.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.2.14.               Market Revenue and Forecast, By End-use (2016-2030)

13.2.14.1.    

13.2.15.               France

13.2.15.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.2.15.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.2.15.3.   Market Revenue and Forecast, By Type (2016-2030)

13.2.15.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.2.16.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.2.16.1.   Market Revenue and Forecast, By End-use (2016-2030)

13.2.17.               Rest of Europe

13.2.17.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.2.17.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.2.17.3.   Market Revenue and Forecast, By Type (2016-2030)

13.2.17.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.2.18.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.2.18.1.   Market Revenue and Forecast, By End-use (2016-2030)

13.3.        APAC

13.3.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

13.3.2.  Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.3.3.  Market Revenue and Forecast, By Type (2016-2030)

13.3.4.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.3.5.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.3.6.  Market Revenue and Forecast, By End-use (2016-2030)

13.3.7.  India

13.3.7.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.3.7.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.3.7.3.      Market Revenue and Forecast, By Type (2016-2030)

13.3.7.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.3.8.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.3.9.  Market Revenue and Forecast, By End-use (2016-2030)

13.3.10.               China

13.3.10.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.3.10.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.3.10.3.   Market Revenue and Forecast, By Type (2016-2030)

13.3.10.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.3.11.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.3.11.1.   Market Revenue and Forecast, By End-use (2016-2030)

13.3.12.               Japan

13.3.12.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.3.12.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.3.12.3.   Market Revenue and Forecast, By Type (2016-2030)

13.3.12.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.3.12.5.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.3.12.6.   Market Revenue and Forecast, By End-use (2016-2030)

13.3.13.               Rest of APAC

13.3.13.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.3.13.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.3.13.3.   Market Revenue and Forecast, By Type (2016-2030)

13.3.13.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.3.13.5.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.3.13.6.   Market Revenue and Forecast, By End-use (2016-2030)

13.4.        MEA

13.4.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

13.4.2.  Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.4.3.  Market Revenue and Forecast, By Type (2016-2030)

13.4.4.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.4.5.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.4.6.  Market Revenue and Forecast, By End-use (2016-2030)

13.4.7.  GCC

13.4.7.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.4.7.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.4.7.3.      Market Revenue and Forecast, By Type (2016-2030)

13.4.7.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.4.8.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.4.9.  Market Revenue and Forecast, By End-use (2016-2030)

13.4.10.               North Africa

13.4.10.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.4.10.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.4.10.3.   Market Revenue and Forecast, By Type (2016-2030)

13.4.10.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.4.11.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.4.12.               Market Revenue and Forecast, By End-use (2016-2030)

13.4.13.               South Africa

13.4.13.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.4.13.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.4.13.3.   Market Revenue and Forecast, By Type (2016-2030)

13.4.13.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.4.13.5.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.4.13.6.   Market Revenue and Forecast, By End-use (2016-2030)

13.4.14.               Rest of MEA

13.4.14.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

13.4.14.2.   Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.4.14.3.   Market Revenue and Forecast, By Type (2016-2030)

13.4.14.4.   Market Revenue and Forecast, By Process Flow (2016-2030)

13.4.14.5.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.4.14.6.   Market Revenue and Forecast, By End-use (2016-2030)

13.5.        Latin America

13.5.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

13.5.2.  Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.5.3.  Market Revenue and Forecast, By Type (2016-2030)

13.5.4.  Market Revenue and Forecast, By Process Flow (2016-2030)

13.5.5.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.5.6.  Market Revenue and Forecast, By End-use (2016-2030)

13.5.7.  Brazil

13.5.7.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.5.7.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.5.7.3.      Market Revenue and Forecast, By Type (2016-2030)

13.5.7.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.5.8.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.5.8.1.      Market Revenue and Forecast, By End-use (2016-2030)

13.5.9.  Rest of LATAM

13.5.9.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

13.5.9.2.      Market Revenue and Forecast, By Product Life Cycle (2016-2030)

13.5.9.3.      Market Revenue and Forecast, By Type (2016-2030)

13.5.9.4.      Market Revenue and Forecast, By Process Flow (2016-2030)

13.5.9.5.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

13.5.9.6.      Market Revenue and Forecast, By End-use (2016-2030)

Chapter 14.  Company Profiles

14.1.              Accenture

14.1.1.  Company Overview

14.1.2.  Product Offerings

14.1.3.  Financial Performance

14.1.4.  Recent Initiatives

14.2.              Linical Accelovance

14.2.1.  Company Overview

14.2.2.  Product Offerings

14.2.3.  Financial Performance

14.2.4.  Recent Initiatives

14.3.              Cognizant

14.3.1.  Company Overview

14.3.2.  Product Offerings

14.3.3.  Financial Performance

14.3.4.  Recent Initiatives

14.4.              Laboratory Corporation of America Holdings

14.4.1.  Company Overview

14.4.2.  Product Offerings

14.4.3.  Financial Performance

14.4.4.  Recent Initiatives

14.5.              IBM Corporation

14.5.1.  Company Overview

14.5.2.  Product Offerings

14.5.3.  Financial Performance

14.5.4.  Recent Initiatives

14.6.              ArisGlobal

14.6.1.  Company Overview

14.6.2.  Product Offerings

14.6.3.  Financial Performance

14.6.4.  Recent Initiatives

14.7.              ICON plc.

14.7.1.  Company Overview

14.7.2.  Product Offerings

14.7.3.  Financial Performance

14.7.4.  Recent Initiatives

14.8.              Capgemini

14.8.1.  Company Overview

14.8.2.  Product Offerings

14.8.3.  Financial Performance

14.8.4.  Recent Initiatives

14.9.              ITClinical.

14.9.1.  Company Overview

14.9.2.  Product Offerings

14.9.3.  Financial Performance

14.9.4.  Recent Initiatives

14.10.           FMD K&L

14.10.1.               Company Overview

14.10.2.               Product Offerings

14.10.3.               Financial Performance

14.10.4.               Recent Initiatives

14.11.           IQVIA

14.11.1.               Company Overview

14.11.2.               Product Offerings

14.11.3.               Financial Performance

14.11.4.               Recent Initiatives

14.12.           TAKE Solutions Ltd.

14.12.1.               Company Overview

14.12.2.               Product Offerings

14.12.3.               Financial Performance

14.12.4.               Recent Initiatives

14.13.           PAREXEL International Corporation

14.13.1.               Company Overview

14.13.2.               Product Offerings

14.13.3.               Financial Performance

14.13.4.               Recent Initiatives

14.14.           BioClinica Inc.

14.14.1.               Company Overview

14.14.2.               Product Offerings

14.14.3.               Financial Performance

14.14.4.               Recent Initiatives

14.15.           Wipro Ltd.

14.15.1.               Company Overview

14.15.2.               Product Offerings

14.15.3.               Financial Performance

14.15.4.               Recent Initiatives

14.16.           United BioSource Corporation

14.16.1.               Company Overview

14.16.2.               Product Offerings

14.16.3.               Financial Performance

14.16.4.               Recent Initiatives

Chapter 15.  Research Methodology

15.1.              Primary Research

15.2.              Secondary Research

15.3.              Assumptions

Chapter 16.  Appendix

16.1.              About Us

Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert